Top Ten most popular articles on Pharmafile.com this week

pharmafile | August 4, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, biotech, drugs, healthcare, life sciences, medicines, pharma, pharmaceuticals, top ten 

Another week passes by, and the headlines have seen some shocking stories, such as the news that the UK is beginning to succumb to the same opioid crisis faced in the US, as deaths related to the class of drug hit a record high.

It’s been a whirlwind few weeks for AstraZeneca, who recently reported the failure of its paramount Mystic trial. Since then, the company has been on damage control, and we have seen a swathe of good news come out of the drug maker in an attempt to win back public and investor confidence. Unsurprisingly, a number of these stories proved popular with our readers.

Also, don’t miss our in-depth feature exploring how the patient’s voice in medical treatment is quickly growing in the considerations of the pharma industry, and what they are doing to listen to what they are saying. 

Check out the week’s ten most popular articles on Pharmafile.com now!

10. Existing arthritis drug could save thousands in blood cancer treatment

New research has indicated that thousands of pounds could be saved in blood cancer treatment by tapping into the unexplored properties of methotrexate, a drug traditionally used to treat inflammatory diseases like rheumatoid arthritis, psoriasis and Crohn’s disease.

9. AstraZeneca’s Priority Review good news provides reprieve

This latest piece of good news for AZ, in receiving a Priority Review for acalabrutinib, comes after the same drug received a breakthrough designation just yesterday based on Phase 2 data for the treatment of mantle cell lymphoma, a type of blood cancer.                                 

8. FDA turns down Janssen’s sirukumab for rheumatoid arthritis

Janssen has suffered a knockback as the FDA refused to recommend sirukumab for the treatment of moderate to severely active forms of the disease.

7. GSK heads down digital path creating specific role for incomer

GSK has created a whole new role to push the company to strengthen its digital, data and analytics strategy, with Karenann Terrel unveiled as the new Chief Digital and Technology Officer.

6. Record number of drug-related deaths, as opioid crisis hits UK

Numbers released by the Office for National Statistics (ONC) has revealed that drug misuse deaths were at a record high, with 3,744 deaths in 2016. This figure is the highest since records began in 1993 and marks an increase in 2% over deaths in 2015.

5. AZ’s ‘blockbuster’ lung cancer drug fails, Q2 revenue falls

The long-awaited results for AstraZeneca’s Mystic trial have been revealed and, in a shocking setback for the company, it was found that its injectable immunotherapy treatmentsdo not outperform standard chemotherapy.

4. Pfizer’s major drug doubles sales but overall revenue falls

Pfizer revealed in its briefing on its second quarter financials that Ibrance, its breast cancer treatment, had grown in sales by 66% but overall revenue was down to $12.9 billion from $13.15 billion.

3. Learning to trust the patient’s voice

Through digital media and technology, the patient’s voice is only growing in strength and it is of growing importance that pharmaceutical industry pays heed to what is being said. Ben Hargreaves observes how developing partnerships are becoming increasingly common and integral to the way pharma interacts with its consumers.

2. EMA reveals ‘business continuity plan’ for Brexit, cuts resources from non-essential areas

Due to the anticipated disruption surrounding the outcome of negotiations, the EMA has released a continuity plan outlining its intentions to mitigate implications on its workload.

1. Pharma companies’ reputations nosediving in the UK, finds report

The reputation of large pharma companies in the UK was revealed to be well below the global average, in PatientView’s annual report. The study asked UK patient groups a range of questions, with the major finding showing that only 25.3% of respondents evaluated the industry as having an ‘Excellent’ or ‘Good’ reputation.

Related Content


First patient dosed in AdvanCell’s phase 1/2 trial for prostate cancer treatment

AdvanCell has announced that the first patient has been dosed with 212Pb-ADVC001 in its phase …

GSK shares results from phase 3 RUBY trial of Jemperli for endometrial cancer treatment

GSK has announced positive headline results from an analysis of part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO …

Nuvectis Pharma initiates phase 1a NXP900 clinical trial

Clinical stage biopharmaceutical company Nuvectis Pharma has announced the initiation of a phase 1a dose …

Latest content